PODXL and myeloid sarcoma: PODXL reportedly increases the aggressive phenotype of numerous types of cancer, including acute myeloid and lymphoid leukemia, myeloid sarcomas, as well as certain breast, liver, pancreatic and kidney tumors (13,14).